Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IGXTNASDAQ:ITRMOTCMKTS:PXSLYNASDAQ:TOCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/AITRMIterum Therapeutics$0.95-1.8%$0.99$0.81▼$3.02$38.56M2.791.07 million shs491,961 shsPXSLYPharmaxis$0.88$0.88$0.62▼$1.47$26.53M1.221,000 shsN/ATOCATocagen$13.66-1.3%$32.24$0.42▼$6.77$326.73M0.011.47 million shs23,706 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%ITRMIterum Therapeutics0.00%-5.84%+0.11%-15.84%-15.09%PXSLYPharmaxis0.00%0.00%0.00%0.00%0.00%TOCATocagen0.00%+11.51%+36.94%+107.60%+2,507.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.9069 of 5 stars3.53.00.00.02.30.00.0PXSLYPharmaxisN/AN/AN/AN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIGXTIntelGenx Technologies 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00846.37% UpsidePXSLYPharmaxis 0.00N/AN/AN/ATOCATocagen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PXSLY, ITRM, IGXT, and TOCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/APXSLYPharmaxis$8.75M3.03N/AN/A$0.04 per share22.00TOCATocagen$40K8,168.34N/AN/A$0.45 per share30.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/AITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)PXSLYPharmaxis-$9.36MN/A0.00∞N/AN/AN/AN/AN/ATOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ALatest PXSLY, ITRM, IGXT, and TOCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/APXSLYPharmaxisN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIGXTIntelGenx TechnologiesN/AN/AN/AITRMIterum TherapeuticsN/A3.723.58PXSLYPharmaxis2.823.312.92TOCATocagen1.881.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIGXTIntelGenx TechnologiesN/AITRMIterum Therapeutics9.21%PXSLYPharmaxisN/ATOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipIGXTIntelGenx Technologies42.05%ITRMIterum Therapeutics9.20%PXSLYPharmaxisN/ATOCATocagen10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionablePXSLYPharmaxis6930.15 millionN/ANot OptionableTOCATocagen7723.92 millionN/ANot OptionablePXSLY, ITRM, IGXT, and TOCA HeadlinesRecent News About These CompaniesTocagen plummets on phase 3 data for glioma therapyFebruary 2, 2025 | pharmaphorum.comPCelgene hopes device + drug can tackle aggressive brain tumoursSeptember 18, 2024 | pharmaphorum.comPForte Biosciences Inc (FBRX)August 7, 2024 | investing.comAnova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM GrantMay 1, 2024 | finance.yahoo.comGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizMarch 25, 2024 | pharmiweb.comPONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline GliomaFebruary 12, 2024 | ascopubs.orgAMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorsJanuary 19, 2024 | eurekalert.orgEForte Biosciences: Changes In Registrant S Certifying AccountantDecember 12, 2023 | cbonds.comCRiskOn International And 3 Other Stocks Under $2 Insiders Are BuyingDecember 11, 2023 | markets.businessinsider.comPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedNovember 6, 2023 | pharmaceutical-technology.comPProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board AppointmentNovember 2, 2023 | finance.yahoo.comFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma PatientsJuly 26, 2023 | precisionmedicineonline.comPGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRMay 12, 2023 | news.google.comNForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comApril 28, 2023 | news.google.comNGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comApril 6, 2023 | news.google.comNBelzutifan plus cabozantinib for patients with advanced clear cell ... - The LancetMarch 31, 2023 | news.google.comNCurrent drug development and trial designs in neuro-oncology ... - The LancetMarch 27, 2023 | news.google.comNCompanion Diagnostics Market is set to experience a significant ... - Digital JournalMarch 27, 2023 | news.google.comNOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital JournalMarch 14, 2023 | news.google.comNAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital JournalMarch 8, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimePXSLY, ITRM, IGXT, and TOCA Company DescriptionsIntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Iterum Therapeutics NASDAQ:ITRM$0.95 -0.02 (-1.76%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$0.95 0.00 (0.00%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Pharmaxis OTCMKTS:PXSLY$0.88 0.00 (0.00%) As of 06/8/2021Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.Tocagen NASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
